## **Biological Agent Reference Sheet (BARS)**

## This content of this document is for Emory University USE ONLY.

The information and contents of this Biological Agent Reference Sheet (including all text and graphics), whether available in print or electronic format (including any digital format, e-mail transmissions, or download from the website), shall be known hereinafter as "Reference Sheet Content". The Reference Sheet Content is provided as a courtesy and is not intended as a sole source of guidance in the evaluation of Biological Agents. The Reference Sheet Content is not intended to substitute for medical advice, medical care, diagnosis or treatment obtained from a physician or health care provider. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not rely on the Reference Sheet Content for diagnosis, treatment, or medical advice. This Reference Sheet Content is for informational purposes and does not provide individualized medical care or treatment. No endorsement of any specific tests, products, or procedures is made by Reference Sheet Content or affiliated party, member, agent or employee of the Emory University Environmental Health and Safety Office.



## **BIOLOGICAL AGENT REFERENCE SHEET**

## Zika Virus (ZIKV)

CHARACTERISTICS			
Morphology	Zika virus (ZIKV) is a single-stranded RNA virus of the Flaviviridae family, genus Flavivirus, Spondweni group. There are two ZIKV lineages: the African lineage and the Asian lineage which has recently		
Growth	emerged in the Pacific and the Americas. Inoculate intracerebrally into suckling mice. Resuspend 20% sMb (sucking mouse brain) with		
Conditions Sources	7.5% BSA in PBS. -ATCC <sup>®</sup> VR84 – from MR766 (original strain) -Wild virus isolated from infected human diagnostic		
Sources	samples		
HEALTH HAZARDS			
Host Range	Humans and NHPs, non-pathogenic for hamster, guinea pig or rabbit.		
Modes of Transmission	ZIKV is transmitted by infected Aedes mosquitoes. Perinatal, in utero, sexual and transfusion transmission events have also been reported.		
Signs and Symptoms	About 1 in 5 people infected with ZIKV become ill. The most common symptoms of Zika are fever, rash, joint pain, or conjunctivitis (red eyes). Other common symptoms include muscle pain and headache. The illness is usually mild with symptoms lasting for several days to a week. There may be an association between ZIKV infection in pregnancy and microcephaly of the fetus.		
Infectious Dose	Unknown		
Incubation Period	The incubation period ranges between approximately three to 12 days after the bite of an infected mosquito. Most of the infections remain asymptomatic (between 60 to 80%).		
MEDICAL PRECAUTIONS / TREATMENT			
Prophylaxis	None		
	Neze		
Vaccines	None		
Vaccines Diagnosis	ZIKV disease diagnostics is primarily based on detection of viral RNA from clinical specimens in acutely ill patients. The viremic period appears to be short, allowing for direct virus detection during the		
	ZIKV disease diagnostics is primarily based on detection of viral RNA from clinical specimens in acutely ill patients. The viremic period appears to be		
Diagnosis	ZIKV disease diagnostics is primarily based on detection of viral RNA from clinical specimens in acutely ill patients. The viremic period appears to be short, allowing for direct virus detection during the first 3–5 days after the onset of symptoms. The treatment is symptomatic and mainly based on pain relief, fever reduction and anti-histamines for pruritic rash. People infected with ZIKV, chikungunya, or dengue virus should be protected from further mosquito exposure during the first few days of illness to prevent other mosquitoes from becoming infected and reduce the risk of local transmission		
Diagnosis Treatment	ZIKV disease diagnostics is primarily based on detection of viral RNA from clinical specimens in acutely ill patients. The viremic period appears to be short, allowing for direct virus detection during the first 3–5 days after the onset of symptoms. The treatment is symptomatic and mainly based on pain relief, fever reduction and anti-histamines for pruritic rash. People infected with ZIKV, chikungunya, or dengue virus should be protected from further mosquito exposure during the first few days of illness to prevent other mosquitoes from becoming infected and reduce		
Diagnosis Treatment Surveillance Emory Requirements	ZIKV disease diagnostics is primarily based on detection of viral RNA from clinical specimens in acutely ill patients. The viremic period appears to be short, allowing for direct virus detection during the first 3–5 days after the onset of symptoms. The treatment is symptomatic and mainly based on pain relief, fever reduction and anti-histamines for pruritic rash. People infected with ZIKV, chikungunya, or dengue virus should be protected from further mosquito exposure during the first few days of illness to prevent other mosquitoes from becoming infected and reduce the risk of local transmission Occupational Health Consultation prior to handling ZIKV. Report all incidents.		
Diagnosis Treatment Surveillance Emory Requirements LABORATORY H Laboratory	ZIKV disease diagnostics is primarily based on detection of viral RNA from clinical specimens in acutely ill patients. The viremic period appears to be short, allowing for direct virus detection during the first 3–5 days after the onset of symptoms. The treatment is symptomatic and mainly based on pain relief, fever reduction and anti-histamines for pruritic rash. People infected with ZIKV, chikungunya, or dengue virus should be protected from further mosquito exposure during the first few days of illness to prevent other mosquitoes from becoming infected and reduce the risk of local transmission Occupational Health Consultation prior to handling ZIKV. Report all incidents.		
Diagnosis Treatment Surveillance Emory Requirements LABORATORY F Laboratory Acquired Infections (LAIs)	ZIKV disease diagnostics is primarily based on detection of viral RNA from clinical specimens in acutely ill patients. The viremic period appears to be short, allowing for direct virus detection during the first 3–5 days after the onset of symptoms. The treatment is symptomatic and mainly based on pain relief, fever reduction and anti-histamines for pruritic rash. People infected with ZIKV, chikungunya, or dengue virus should be protected from further mosquito exposure during the first few days of illness to prevent other mosquitoes from becoming infected and reduce the risk of local transmission Occupational Health Consultation prior to handling ZIKV. Report all incidents.		
Diagnosis Treatment Surveillance Emory Requirements LABORATORY H Laboratory Acquired	ZIKV disease diagnostics is primarily based on detection of viral RNA from clinical specimens in acutely ill patients. The viremic period appears to be short, allowing for direct virus detection during the first 3–5 days after the onset of symptoms. The treatment is symptomatic and mainly based on pain relief, fever reduction and anti-histamines for pruritic rash. People infected with ZIKV, chikungunya, or dengue virus should be protected from further mosquito exposure during the first few days of illness to prevent other mosquitoes from becoming infected and reduce the risk of local transmission Occupational Health Consultation prior to handling ZIKV. Report all incidents.		
Diagnosis Treatment Surveillance Emory Requirements LABORATORY F Laboratory Acquired Infections (LAIs)	ZIKV disease diagnostics is primarily based on detection of viral RNA from clinical specimens in acutely ill patients. The viremic period appears to be short, allowing for direct virus detection during the first 3–5 days after the onset of symptoms. The treatment is symptomatic and mainly based on pain relief, fever reduction and anti-histamines for pruritic rash. People infected with ZIKV, chikungunya, or dengue virus should be protected from further mosquito exposure during the first few days of illness to prevent other mosquitoes from becoming infected and reduce the risk of local transmission Occupational Health Consultation prior to handling ZIKV. Report all incidents. Accidental infection has occurred in laboratory personnel Unknown		

	ection/factsheet-health- professionals/Pages/factsheet_health_professionals.a spx#sthash.Xj8UPvQH.dpuf		
CDC	http://www.cdc.gov/zika/prevention/index.html http://www.cdc.gov/biosafety/publications/bmbl5/b mbl5_sect_viii_f.pdf		
ATTC	http://www.atcc.org/products/all/VR- 84.aspx#documentation		
CONTAINMENT			
BSL2+/ABSL2+	Appropriate safety procedures should always be used with this material. See BMBL Section VIIIF. Biosafety containment requirements: BSL2+/ABSL2+ means BSL2 containment with BSL3 practices and or PPE. Lab specific procedures (SOPs) will outline specific containment and practices and PPE.		
SPILL PROCEDURES			
Small	Notify others working in the lab. Allow aerosols to settle. Don appropriate PPE. Cover area of the spill with paper towels and apply an EPA approved disinfectant, working from the perimeter towards the center. Allow 30 minutes of contact time before disposal and cleanup of spill materials.		
Large	Contact Emory's Biosafety Officer (404-727-8863), the EHSO Office (404-727-5922), or The Spill Response Team (404-727-2888).		
EXPOSURE PRO	CEDURES		
Mucous		e for 15 minutes at eyewash	
membrane	station.		
Other Exposures		water for 15 minutes.	
Reporting	Immediately report incident to supervisor, complete an employee incident report in PeopleSoft.		
Medical Follow- up	Zam-4pm (OIM):   EUH (404-686-7941)   EUHM (404-686-7106)   WW (404-728-6431)   Needle Stick (OIM):   EUH (404-686-8587)   EUHM (404-686-2352)	After Hours:   OIM NP On Call   404-686-5500   PIC# 50464   Yerkes: Maureen Thompson   Office (404-727-8012)   Cell (404-275-0963)	
VIABILITY			
Disinfection	Unknown. Other flaviviruses are susceptible to 70% ethanol, 10% bleach, and 2% glutaraldehyde		
Inactivation Survival Outside Host	Inactivated by heat and low pH. Unknown.		
PERSONAL PRO	TECTIVE EQUIPMENT (PPE)	)	
Minimum PPE Requirements	At minimum, personnel are required to don gloves, closed toed shoes, lab coat, and appropriate face and eye protection when working with <i>ZIKV</i> . Additional PPE may be required depending on lab specific SOPs and containment.		
Additional Precautions	All procedures that may produce aerosols, or involve high concentrations or large volumes should be conducted in a biological safety cabinet (BSC). The use of needles, syringes, and other sharp objects should be strictly limited. Additional precautions should be considered with work involving animals or large scale activities.		